Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a  description of the sensitizers used to overcome resistance to anti-EGFR  targeted antibody therapies in cancer, including novel engineered  antibody drugs and other sensitizers. The book gives insights into the  landscape of anti-EGFR based cancer treatments, the challenges of  targeted therapy, and a glimpse into the future of antibody therapy. It  offers pertinent science information on strategies used for the rational  design and discovery of novel sensitizing agents, and in addition,  translational studies involving pre-clinical and clinical design. This  book is an indispensable resource for cancer researchers, medicinal  chemists and other biomedical scientists.

Finally, the book  covers basic science strategies used in drug discovery and preclinical  evaluation focused on EGFR blockage resistance, as well as clinical  trial methodology, including clinical pharmacokinetics and imaging to  address issues of efficacy evaluation of the new anticancer sensitizers  for anti-EGFR drug resistance.